Brokerages Set Fresenius Medical Care Corporation (NYSE:FMS) Price Target at $48.67

Shares of Fresenius Medical Care Corporation (NYSE:FMS) have been given an average rating of “Buy” by the thirteen brokerages that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and eight have given a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $48.67.

A number of research firms recently weighed in on FMS. UBS AG reissued a “sell” rating on shares of Fresenius Medical Care Corporation in a research note on Tuesday, July 4th. BidaskClub cut shares of Fresenius Medical Care Corporation from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Nord/LB reissued a “buy” rating on shares of Fresenius Medical Care Corporation in a research note on Wednesday, June 28th. Royal Bank Of Canada reaffirmed a “neutral” rating and set a price objective on shares of Fresenius Medical Care Corporation in a research note on Tuesday. Finally, DZ Bank AG reaffirmed a “neutral” rating on shares of Fresenius Medical Care Corporation in a research note on Monday, May 29th.

Shares of Fresenius Medical Care Corporation (NYSE FMS) traded up 2.0449% during trading on Monday, reaching $45.8692. 179,037 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $47.76 and a 200-day moving average price of $44.72. The company has a market capitalization of $28.15 billion, a PE ratio of 20.0302 and a beta of 0.47. Fresenius Medical Care Corporation has a 52-week low of $38.05 and a 52-week high of $50.22.

Fresenius Medical Care Corporation (NYSE:FMS) last posted its earnings results on Tuesday, August 1st. The company reported $0.48 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.53 by $0.05. The business had revenue of $4.47 billion during the quarter, compared to the consensus estimate of $5.20 billion. Fresenius Medical Care Corporation had a net margin of 7.06% and a return on equity of 11.57%. The business’s revenue was up 11.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.96 EPS. On average, equities analysts forecast that Fresenius Medical Care Corporation will post $2.33 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Brokerages Set Fresenius Medical Care Corporation (NYSE:FMS) Price Target at $48.67” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/08/19/fresenius-medical-care-corporation-nysefms-given-average-recommendation-of-buy-by-brokerages-updated-updated-updated.html.

A number of hedge funds have recently modified their holdings of FMS. UBS Asset Management Americas Inc. purchased a new stake in shares of Fresenius Medical Care Corporation during the fourth quarter valued at $1,133,000. Harding Loevner LP raised its position in shares of Fresenius Medical Care Corporation by 7.1% in the first quarter. Harding Loevner LP now owns 3,528,960 shares of the company’s stock worth $148,675,000 after buying an additional 233,347 shares during the last quarter. Quadrant Capital Group LLC raised its position in shares of Fresenius Medical Care Corporation by 12.7% in the first quarter. Quadrant Capital Group LLC now owns 3,736 shares of the company’s stock worth $149,000 after buying an additional 420 shares during the last quarter. Capstone Asset Management Co. raised its position in shares of Fresenius Medical Care Corporation by 4.1% in the first quarter. Capstone Asset Management Co. now owns 59,740 shares of the company’s stock worth $2,517,000 after buying an additional 2,380 shares during the last quarter. Finally, Telemus Capital LLC bought a new position in shares of Fresenius Medical Care Corporation during the first quarter worth about $325,000. 2.84% of the stock is currently owned by hedge funds and other institutional investors.

Fresenius Medical Care Corporation Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Analyst Recommendations for Fresenius Medical Care Corporation (NYSE:FMS)

What are top analysts saying about Fresenius Medical Care Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fresenius Medical Care Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit